Maslova V. Optimization of treatment of patients with influenza and other acute respiratory viral infections using inhalation therapy

The thesis is a clinical study to optimize the treatment of patients with influenza and other acute respiratory viral infections. Clinical material contains the results of observations of 216 patients aged 18 to 43 years: 64 patients with influenza and 152 patients with acute respiratory viral infections (ARVI) who were inpatient treatment at the Regional Clinical Infectious Diseases Hospital in Kharkiv. Depending on the intended treatment, the patients were divided into groups as follows: the control group received standard therapy (32 patients with influenza and 93 patients with other ARIs); the main group - on the background of standard therapy received cycloferon inhalations (32 patients with influenza and 59 patients with other ARIs). Clinical, anamnestic, laboratory, immunological, instrumental, and statistical methods of investigation were used to assess the patients' condition and to compare the results of the treatment of patients with influenza and ARVI. The individual tolerability of cycloferon inhalations was evaluated by the effects of one procedure on health, hemodynamics (blood pressure, heart rate), and respiratory rate in patients with influenza and other ARVIs compared to placebo (inhalation of distilled water). The effectiveness of the first procedure for inhaling cycloferon (based on the temperature level) on the background of standard therapy was also evaluated. At the same time, 32 patients with influenza and 32 patients with ARVI evaluated the cytokine status according to the dynamics of cytokine concentration in saliva and blood by solid phase IFA. Medicinal treatment of patients with influenza and ARIs was carried out in accordance with the protocols drawn up on the basis of current normative documents in Ukraine. Inhalations of cycloferon were administered in a dose of 2.0 ml of a 12.5% aqueous solution to which 2.0 ml of saline solution was added, for a duration of 10 to 20 minutes daily (with the help of a three-mode compressor nebulizer "Dolphin" manufactured by the company "Flame Noova" (Italy ) in different modes using "Rapid Flame 2" and "Rapid Flame 6 Plus" sprays. The choice of inhalation regimen or their combination depended on the level of respiratory tract damage. The results of one-time trials showed that cyclopherone inhalations were clinically well tolerated by patients with influenza and ARVI, reduced the frequency of heart rate and respiratory rate without significant differences from placebo, and the first inhalation of cycloferon potentiated standard therapy for lowering body temperature, reducing catarrhal manifestations of the disease in these sick It has been shown that the use of cyclopherone inhalations increased the efficacy of treatment of patients with influenza: shortened the treatment period by 1.6 times, duration of fever and catarrhal syndrome up to 3 days in 66 and 59% of patients, reduced the frequency of complications, the level of proinflammatory cytokines in serum, saliva , increased the level of anti-inflammatory cytokines in serum and saliva, more significantly than the dynamics of parameters in patients receiving only standard drug therapy (p <0.001). The result of the research was to substantiate the possibility and feasibility of using cyclopherone inhalations in patients with influenza and other ARVI (patent for utility model No. 86926, registered in the State Register of Patents of Ukraine on utility models, 10.01.2014).